Our portfolio company Axithra strength Board of Directors
We Venture Capital are pleased to share the news that Axithra has strengthening their Board of Directors. Alain Pluquet, PhD and Michael Tillmann have been appointed as chairman and independent director, respectively.
About We Venture Capital
We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the diagnostics area. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments.
We invest in and partner with early-stage startups close to market entry or early scale-ups, working close with our portfolio to support their growth over time. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare.
About Axithra
Axithra is a spin-off from Ghent University and imec, developing a platform to quickly and accurately measure and monitor drug concentrations in blood, paving the way for treatments tailored to the specific needs of each individual, at any given time.
The first application is focusing on personalizing beta-lactam antibiotics treatments in the intensive care unit. The company’s platform is based on proprietary optical and photonics technology and will allow physicians to optimize patient care by enabling personalized treatments.